Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 391

A Single Centre Experience from India on the Safety and Efficacy of Cipla Etanercept and Intas Etanercept and Its Comparison with Reference Etanercept(Enbrel) in Children with JIA

9:00AM-11:00AM: Abstract Number: 406

Adults with Juvenile Idiopathic Arthritis Are Not Adults with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 393

Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 381

Calprotectin As a Multipotent Biomarker in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 397

Comorbidities Associated with Pediatric Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 407

Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA

9:00AM-11:00AM: Abstract Number: 408

Development and Initial Validation of the Parent and Child Versions of the Juvenile Arthritis Disease Activity Score

9:00AM-11:00AM: Abstract Number: 409

Discordance Between Physician, Patient, and Parent Disease Assessment Scores in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 404

Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era

9:00AM-11:00AM: Abstract Number: 394

Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 399

Enthesitis in Juvenile Idiopathic Arthritis (JIA)

9:00AM-11:00AM: Abstract Number: 411

Evaluating Levels of Activity and Health-Related Quality of Life in a Cohort of Youth Athletes with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 400

Foot Involvement in Enthesitis-Related Arthritis Subtype of Juvenile Idiopathic Arthritis: Clinical, Radiological and Functional Assessment

9:00AM-11:00AM: Abstract Number: 413

Golimumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 7 Cases and Literature Review

9:00AM-11:00AM: Abstract Number: 403

High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting

9:00AM-11:00AM: Abstract Number: 401

Humoral Immune Response after a Booster Dose with Tdap in Children and Adolescents with Juvenile Idiopathic Arthritis on Anti-TNF and in Healthy Controls

9:00AM-11:00AM: Abstract Number: 380

Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 389

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry

9:00AM-11:00AM: Abstract Number: 386

Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis

9:00AM-11:00AM: Abstract Number: 412

Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder

9:00AM-11:00AM: Abstract Number: 405

Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 396

Performance of Disease Activity Measures in Juvenile Spondyloarthritis in a Placebo Controlled Trial with Infliximab

9:00AM-11:00AM: Abstract Number: 388

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 383

Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt

9:00AM-11:00AM: Abstract Number: 398

Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study

9:00AM-11:00AM: Abstract Number: 415

Proposal for a Damage Index for Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)

9:00AM-11:00AM: Abstract Number: 414

Proposal for the Definition of Inactivity of Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)

9:00AM-11:00AM: Abstract Number: 387

Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 392

Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 385

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease

9:00AM-11:00AM: Abstract Number: 410

Sleep and Its Relationship to Pain and Disease Activity in Turkish Children and Adolescent with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 395

The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA

9:00AM-11:00AM: Abstract Number: 402

The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 382

Tumor Necrosis Factor-α -308 a/G Gene Polymorphism in Children with Juvenile Idiopathic Arthritis: Relation to Disease Activity, Damage and Disability

9:00AM-11:00AM: Abstract Number: 417

Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis

9:00AM-11:00AM: Abstract Number: 390

Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India

9:00AM-11:00AM: Abstract Number: 416

Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].